Advances in Human Monkeypox Vaccines Effectiveness, Safety and Hesitancy

Dear Colleagues,

The human monkeypox (HMPX) outbreak of 2022 did not only cause several thousands of cases in non-endemic countries but also triggered multi-faceted debates about epidemic preparedness, discontinuation of smallpox vaccination, effectiveness and safety of the repurposed smallpox vaccines and drugs, and public interest in (acceptance of) immunization against orthopoxviruses.

I am pleased to invite you to participate in this Special Issue which aims to delve into three main thematic areas around HMPX vaccination.

Firstly, the effectiveness of the repurposed smallpox vaccines that are used as pre- or post-exposure prophylaxis needs to be evaluated within the context of the ongoing outbreak, especially among high-risk groups and healthcare settings.

Secondly, pre- and post-authorization safety of HMPX vaccines and antivirals should be actively monitored in order to update the current immunization guidelines in light of the best available evidence.

Thirdly, vaccination acceptance and misconceptions among healthcare professionals, students, and high-risk groups are of utmost importance amid this outbreak because they may either accelerate or unnecessarily delay the task of epidemic control.

I look forward to receiving your contributions.

Dr. Abanoub Riad
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the Special Issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.